ClinicalTrials.gg
CompletedNCT03379519Updated Feb 20, 2020

Protocol of Multi-domain Attention Training

An interventional study of Multi-domain Attention Training (MAT) and Passive information activities (PIA) in Mild Cognitive Impairment, sponsored by Ministry of Science and Technology, Taiwan. Completed. Per ClinicalTrials.gov, last updated 2020-02-20.

Sponsored by Ministry of Science and Technology, Taiwan · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Aug 2016, registered Dec 2017).
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Sex
All
01

Study summary

This study sought to investigate the changes in attention in older adults with mild cognitive impairment after Multi-domain Attention Training .

Read the detailed description

This double-blind randomized controlled study has a 2-arm parallel group design. All subjects will be randomized by the block randomization, into intervention group (Multi-domain Attention Training, MAT), or active control group (Passive information activities, PIA). Training sessions of the MAT group are 45 minutes/day, 3 days/week, for 12 weeks (36 sessions each). The training of PIA group is the same as MAT group. The investigators constructed a rigorous MAT program adhering to the Consolidated Standards of Reporting Trials (CONSORT) reporting guidelines. The investigators expect to determine the improvement in attention function of older adults with mild cognitive impairment after using the MAT program.

02

Conditions studied

  • Mild Cognitive Impairment
03

In context

Cognitive Dysfunction

3,875 studies on the registry are indexed under Cognitive Dysfunction; 1,121 are open to participants now.

This study's planned enrollment of 60 is close to the median of 64 across 2,796 interventional studies indexed under Cognitive Dysfunction.

Browse Cognitive Dysfunction studies →

Lead sponsor

Ministry of Science and Technology, Taiwan is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must endorse at least two items from a list of frequent subjective memory complaints by patient and/or an informant
  • Objective memory impairment on neuropsychological tests of memory 1.5 SD or more below age/education norms
  • Clinical neurologic examination by the (MMSE) score of 24 or higher
  • No impairment in personal activities of daily living (P-ADL) as determined by clinical interview with participant and family

Exclusion criteria

Exclusion Criteria:

  • The clinical diagnosis of dementia was based on the
  • Active in another cognitive or memory-related training in the past year
  • Comorbid medical conditions that would predispose them to imminent functional decline or cognitive impairment
  • A diagnosis of major neurological or psychiatric illness history and/or behavioral problems that would sufficiently impair performance to make participation impossible
  • Severe losses in vision, hearing, or communicative ability
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Multi-domain Attention Training (MAT)

    Training sessions of the MAT group is 45 minutes/day, 3 sessions/week, for 12 weeks (36 sessions).

    Behavioral: Multi-domain Attention Training (MAT)

  • Active comparator
    Passive information activities (PIA)

    The training sessions of PIA is the same as MAT group (45 min/day, 3 days/week, for 12 weeks, for a total of 36 sessions).

    Behavioral: Passive information activities (PIA)

Interventions

  • BehavioralMulti-domain Attention Training (MAT)

    The training content emphasis three concept of attention include: intensity of attention, executive attention, and spatial orienting attention.

    Also known as: Attention training

  • BehavioralPassive information activities (PIA)

    The active control group (Passive information activities) training content included reading online e-books and playing online games.

    Also known as: Active control group

06

What researchers measure

Primary outcomes

  1. Change in attention as measured by the Digit Span Task (DS).

    The primary outcome indicators is executive attention assessed by the Digit Span Task (DS).

    Time frame: Change from baseline in executive attention at Immediate post-test, 3 months, 6 months after intervention.

Secondary outcomes

  1. Change in attention as measured by the Trail Making Test (TMT).

    The secondary outcome indicator is spatial orienting attention evaluated by the Trail Making Test.

    Time frame: Change from baseline in spatial orienting attention at Immediate post-test, 3 months, 6 months after intervention.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in May 2019, 33 months.

Of 1,445 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's 33 months is above that.

Counting every sponsor, half of 1,514 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2017
First posted
Dec 20, 2017
StartActual
Aug 1, 2016
Primary completionActual
May 31, 2019
CompletionActual
Dec 31, 2019
Last update
Feb 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03379519
Lead sponsor
Ministry of Science and Technology, Taiwan
Responsible party
Yang, Hui-Ling (Ph.D. candidate, Ministry of Science and Technology, Taiwan) — Principal investigator
First posted
Dec 20, 2017
Start date
Aug 1, 2016
Primary completion
May 31, 2019
Completion
Dec 31, 2019
Last update
Feb 20, 2020

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion